Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat, showing statistically significant hemoglobin improvement and clinically meaningful reductions in transfusion burden and sickle cell pain crises among responders. The data reinforces mitapivat's strong anti-hemolytic profile and potential to improve quality…